التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Biogen Inc
Open
Sector Healthcare
157.49 2.37
Overview
Share price change
24h
Min
153.77
Max
157.94
Income | -195M 389M |
|---|---|
Sales | 2.5B |
P/E Sector Avg | 28.98 94.998 |
EPS | 4.08 |
Profit margin | 15.729 |
Employees | 7,570 |
EBITDA | -157M 762M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +60.54 upside |
Next Earnings | ١١ فبراير ٢٠٢٥ |
|---|
Market Cap | -1.6B 24B |
|---|---|
Previous open | 155.12 |
Previous close | 157.49 |
News Sentiment
By Acuity
41%
59%
159 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Biogen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Biogen Inc Forecast
Price Target
By TipRanks
60.54% upside
12 Months Forecast
Average 249.52 USD 60.54%
High 315 USD
Low 180 USD
Based on 25 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.
Sentiment
By Acuity
159 / 392 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Biogen Inc
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
